文献速递细菌感染、耐药与抗菌药物医院感染防控

医疗照护相关性肺炎:2019年是否还应继续使用这一标签?

Healthcare-associated pneumonia: is there any reason to continue to utilize this label in 2019?
PubMed 文献 · Clin Microbiol Infect · 2019-02-27

本文系统综述2014至2018年文献,比较医疗照护相关性肺炎(HCAP)与社区获得性肺炎(CAP)患者特征。HCAP患者年龄更大、合并症更多,病死率5%至33%,但广谱治疗未降低病死率,HCAP标准预测多重耐药(MDR)病原体性能差,新评分DRIP优于HCAP。建议不再用HCAP识别MDR风险患者。

要点

  • HCAP患者较CAP患者年龄更大、合并症更多,但广谱治疗未降低病死率。
  • HCAP标准预测MDR病原体性能差,新评分DRIP优于HCAP。
  • 合并症与功能状态而非微生物模式似乎解释病死率升高。

核心结论

  • HCAP不应再用于识别MDR病原体感染风险患者。
  • 应使用经过验证的预测评分,结合降阶梯策略和个体化评估合并症与功能状态。

研究设计与样本

  • 系统文献综述,检索PubMed数据库2014至2018年文献,比较HCAP与CAP患者临床特征。

主要发现

  • HCAP患者年龄更大且合并症更高。
  • HCAP病死率范围为5%至33%,但似乎低于早期报告。
  • HCAP分类标准在不同人群中差异很大。
  • 微生物模式显示耐甲氧西林金黄色葡萄球菌(MRSA)和铜绿假单胞菌发生率更高,肠杆菌科细菌程度较低。
  • 四项观察性研究中,遵循指南的广谱治疗未降低病死率。

关键数值与推荐

  • HCAP标准作为预测MDR肺炎或CAP治疗未覆盖病原体的工具表现不佳。
  • 新评分DRIP在预测MDR病原体方面优于HCAP。

临床怎么用

  • 临床不应再使用HCAP标签识别MDR风险患者。
  • 建议使用验证过的预测评分如DRIP,并实施降阶梯策略。
  • 应仔细个体化评估合并症和功能状态。

局限性

  • HCAP分类标准在人群中差异很大,定义和MDR肺炎发生率也差异显著。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is an ongoing controversy on the role of the healthcare-associated pneumonia (HCAP) label in the treatment of patients with pneumonia. OBJECTIVE: To provide an update of the literature on patients meeting criteria for HCAP between 2014 and 2018. SOURCES: The review is based on a systematic literature search using PubMed-Central full-text archive of biomedical and life sciences literature at the U.S. National Institutes of Health's National Library of Medicine (NIH/NLM). CONTENT: Studies compared clinical characteristics of patients with HCAP and community-acquired pneumonia (CAP). HCAP patients were older and had a higher comorbidity. Mortality rates in HCAP varied from 5% to 33%, but seemed lower than those cited in the initial reports. Criteria behind the HCAP classification differed considerably within populations. Microbial patterns differed in that there was a higher incidence of methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa, and, to a lesser extent, enterobacteriaceae. Definitions and rates of multidrug-resistant (MDR) pneumonia also varied considerably. Broad-spectrum guideline-concordant treatment did not reduce mortality in four observational studies. The HCAP criteria performed poorly as a predictive tool to identify MDR pneumonia or pathogens not covered by treatment for CAP. A new score (Drug Resistance in Pneumonia, DRIP) outperformed HCAP in the prediction of MDR pathogens. Comorbidity and functional status, but not different microbial patterns, seem to account for increased mortality. IMPLICATIONS: HCAP should no longer be used to identify patients at risk of MDR pathogens. The use of validated predictive scores along with implementation of de-escalation strategies and careful individual assessment of comorbidity and functional status seem superior strategies for clinical management.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Ewig S, Kolditz M, Pletz MW, et al. Healthcare-associated pneumonia: is there any reason to continue to utilize this label in 2019? Clin Microbiol Infect. 2019. PMID: 30825674. doi:10.1016/j.cmi.2019.02.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。